How to assess the onset of antidepressant effect: Comparison of global ratings and findings based on depression scales

被引:19
作者
Moller, HJ
Muller, H
Volz, HP
机构
[1] UNIV BONN, DEPT PSYCHIAT, W-5300 BONN, GERMANY
[2] UNIV JENA, DEPT PSYCHIAT, O-6900 JENA, GERMANY
关键词
D O I
10.1055/s-2007-979545
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The timing of clinical drug effects in depression can be estimated by a variety of methodological approaches, which might account for the heterogeneity of findings. We compared the patients' own ratings of the onset of antidepressant effect with onset estimations that were based on the intraindividual courses of depression as measured by the Hamilton Depression Rating Scale and a self-rating scale, the von Zerssen Adjective Mood Scale. The data of two control-group studies on brofaromine vs. imipramine were reanalyzed, the first, comprising 224 non-elderly and the second 195 elderly patients. In both studies the patients rated a significantly earlier onset of activity (means: days 12 and 16) than any other method. The means of the scale-based ratings varied between days 20 and 31 and showed a marked dependence on the response criteria selected: strict response criteria produced later onset estimations than less strict ones. Whereas the patient's own ratings indicated a significantly later onset of activity in the elderly patients, none of the scale-based measures supported this difference. The discussion focuses on the importance of methodological aspects.
引用
收藏
页码:57 / 62
页数:6
相关论文
共 15 条
[1]  
[Anonymous], ASSESSMENT DEPRESSIO
[2]   A RATING SCALE FOR DEPRESSION [J].
HAMILTON, M .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1960, 23 (01) :56-62
[3]   THE TIMING, SPECIFICITY AND CLINICAL-PREDICTION OF TRICYCLIC DRUG EFFECTS IN DEPRESSION [J].
KATZ, MM ;
KOSLOW, SH ;
MAAS, JW ;
FRAZER, A ;
BOWDEN, CL ;
CASPER, R ;
CROUGHAN, J ;
KOCSIS, J ;
REDMOND, E .
PSYCHOLOGICAL MEDICINE, 1987, 17 (02) :297-309
[4]  
LYDIARD RB, 1984, PSYCHOPHARMACOL BULL, V20, P258
[5]  
MEYA U, 1990, TW NEUROLOGIE PSYCHI, V4, P831
[6]   NEUROLEPTIC TREATMENT OF NEGATIVE SYMPTOMS IN SCHIZOPHRENIC-PATIENTS - EFFICACY PROBLEMS AND METHODOLOGICAL DIFFICULTIES [J].
MOLLER, HJ .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 1993, 3 (01) :1-11
[7]   BROFAROMINE IN MAJOR DEPRESSED-PATIENTS - A CONTROLLED CLINICAL-TRIAL VERSUS IMIPRAMINE AND OPEN FOLLOW-UP OF UP TO ONE YEAR [J].
MOLLER, HJ ;
VOLZ, HP .
JOURNAL OF AFFECTIVE DISORDERS, 1992, 26 (03) :163-172
[9]  
QUITKIN FM, 1984, ARCH GEN PSYCHIAT, V41, P782
[10]  
QUITKIN FM, 1987, ARCH GEN PSYCHIAT, V44, P259